160677-41-8

Basic information

• Product Name: MONO-6-N-DIBOC-GUANYL-1,6-HEXADIAMINE
• Synonyms: MONO-6-N-DIBOC-GUANYL-1,6-HEXADIAMINE;tert-butyl -N-[(6-aminohexylamino)-(tert-butoxycarbonylamino)methylene]carbamate
• CAS NO: 160677-41-8
• Molecular Formula: C₁₇H₃₄N₄O₄
• Molecular Weight: 358.48
• Mol File: 160677-41-8.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Density: 1.086g/cm³
• Refractive Index: 1.496
• Solubility: Chloroform, Methanol
• CAS DataBase Reference: MONO-6-N-DIBOC-GUANYL-1,6-HEXADIAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: MONO-6-N-DIBOC-GUANYL-1,6-HEXADIAMINE(160677-41-8)
• EPA Substance Registry System: MONO-6-N-DIBOC-GUANYL-1,6-HEXADIAMINE(160677-41-8)

Safety Data

• Hazardous Substances Data: 160677-41-8(Hazardous Substances Data)

Usage

Description

MONO-6-N-DIBOC-GUANYL-1,6-HEXADIAMINE, also known as N,N''-[(6-Aminohexyl)carbonimidoyl]bis-carbamic Acid C,C''-Bis(1,1-dimethylethyl) Ester, is a chemical compound that serves as an intermediate in the synthesis of Chlorhexidine Digluconate Impurity N-d4 Hydrochloride (C377662). This impurity is a degradation product found in chlorhexidine digluconate solutions, which are widely used for their antimicrobial properties.

Uses

Used in Pharmaceutical Industry:
MONO-6-N-DIBOC-GUANYL-1,6-HEXADIAMINE is used as an intermediate in the synthesis of Chlorhexidine Digluconate Impurity N-d4 Hydrochloride (C377662) for the production of chlorhexidine digluconate solutions. These solutions are utilized for their antimicrobial properties in various medical and dental applications, such as preoperative skin preparation, hand hygiene, and oral care.
Used in Quality Control and Regulatory Compliance:
In the pharmaceutical industry, MONO-6-N-DIBOC-GUANYL-1,6-HEXADIAMINE plays a crucial role in ensuring the quality and safety of chlorhexidine digluconate solutions. By monitoring the presence of this impurity, manufacturers can maintain regulatory compliance and ensure that their products meet the required standards for purity and efficacy.

InChI:InChI=1/C17H34N4O4/c1-16(2,3)24-14(22)20-13(19-12-10-8-7-9-11-18)21-15(23)25-17(4,5)6/h7-12,18H2,1-6H3,(H2,19,20,21,22,23)

Upstream product

• 124-09-4 1,6-Hexanediamine 
• 322474-21-5 N,N'-bis-Boc-S-methyl-isothiourea 
• 145013-05-4 tert-butyl N-({[(tert-butoxy)carbonyl]amino}methanethioyl)carbamate 
• 207857-15-6 1,3-di(tert-butyloxycarbonyl)-2-(trifluoromethylsulfonyl)guanidine 
• 322474-21-5 1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea 
• 152120-54-2 N,N'-bis( tert-butoxycarbonyl)-1H-pyrazole-1-carboxamidine 

Downstream Products

• 1027196-76-4 C₂₃H₄₂N₄O₇ 
• 1026544-39-7 C₂₈H₄₄N₄O₇ 
• 160677-77-0 3-<<(1,1-dimethylethoxy)carbonyl>amino>-12-oxo-2,4,11,14-tetraazapentadec-2-enedioic acid, 1-(1,1-dimethylethyl)ester 15-phenylmethyl ester 
• 170367-39-2 [4-[[3-[[(1,1-dimethylethoxy)carbonyl]amino]butyl](phenylmethyl)amino]butyl]carbamic acid, 11-[[(1,1-dimethylethoxy)carbonyl]amino]-15,15-dimethyl-2,13-dioxo-14-oxa-3,4,12-triaza-11-hexadecen-1-yl ester 
• 252353-76-7 C₄₁H₇₁N₇O₉ 
• 170367-78-9 [4-[[3-[[(1,1-dimethylethoxy)carbonyl]amino]butyl](phenylmethyl)amino]butyl]carbamic acid, 11-[[(1,1-dimethylethoxy)carbonyl]amino]-15,15-dimethyl-2,13-dioxo-14-oxa-3,4,12-triaza-11-hexadecen-1-yl ester (R) 
• 170367-79-0 [4-[[3-[[(1,1-dimethylethoxy)carbonyl]amino]butyl](phenylmethyl)amino]butyl]carbamic acid, 11-[[(1,1-dimethylethoxy)carbonyl]amino]-15,15-dimethyl-2,13-dioxo-14-oxa-3,4,12-triaza-11-hexadecen-1-yl ester (S) 
• 252353-78-9 C₄₀H₆₆F₃N₇O₉ 
• 252353-77-8 C₄₅H₇₁N₇O₉ 
• 365568-05-4 (E)-6-[N²,N³-bis(tert-butoxycarbonyl)guanidino]-1-[(3,4-dimethoxycinnamoyl)amino]hexane 
• 160677-73-6 C₄₄H₇₅N₇O₁₁ 
• 160677-68-9 2-[[[4-[[3-(Amino)propyl]amino]butyl]amino]carbonyloxy]-N-[6-[(aminoiminomethyl) amino]hexyl]acetamide tris(trifluoroacetate) 
• 160677-72-5 1-(1,1-dimethylethyl) 3-[[(1,1-dimethylethoxy)carbonyl]amino]-13-(phenylmethoxy)-12-oxo-2,4,11-triazatetradec-2-enedioate 
• 221250-86-8 C₂₇H₄₂N₄O₇ 

Relevant articles and documents

Modification of Biphenolic Anti-Bacterial to Achieve Broad-Spectrum Activity

The Gram-positive bacteria, methicillin-resistant Staphylococcus aureus (MRSA) and Gram-negative bacteria, Acinetobacter baumannii, are pathogens responsible for millions of nosocomial infections worldwide. Due to the threat of bacteria evolving resistance to antibiotics, scientists are constantly looking for new classes of compounds to treat infectious diseases. The biphenolic analogs of honokiol that were most potent against oral bacteria had similar bioactivity against MRSA. However, all the compounds proved ineffective against A. baumannii. The inability to inhibit A. baumannii is due to the difficult-to-penetrate lipopolysaccharide-coated outer membrane that makes it challenging for antibiotics to enter Gram-negative bacteria. The C 2 scaffold was optimized from the inhibition of Gram-positive bacteria to broad-spectrum antibacterial compounds that inhibit the dangerous Gram-negative pathogen A. baumannii.

Structure-Activity Relationship of Hetarylpropylguanidines Aiming at the Development of Selective Histamine Receptor Ligands?

New classes of alkylated hetarylpropylguanidines with different functionality and variation in spacer length were synthesized to determine their behavior at the four histamine receptor (H1R, H2R, H3R, H4R) subtypes. Alkylated guanidines with different terminal functional groups and varied basicity, like amine, guanidine and urea were developed, based on the lead structure SK&F 91486 (2). Furthermore, heteroatomic exchange at the guanidine structure of 2 led to simple analogues of the lead compound. Radioassays at all histamine receptor subtypes were accomplished, as well as organ bath studies at the guinea pig (gp) ileum (gpH1R) and right atrium (gpH2R). Ligands with terminal functionalization led to, partially, highly affine and potent structures (two digit nanomolar), which showed up a bad selectivity profile within the histamine receptor family. While the benzoylurea derivative 144 demonstrated a preference towards the human (h) H3R, S-methylisothiourea analogue 143 obtained high affinity at the hH4R (pKi=8.14) with moderate selectivity. The molecular basis of the latter finding was supported by computational studies.

Macrocyclization of di-Boc-guanidino-alkylamines related to guazatine components: Discovery and synthesis of innovative macrocyclic amidinoureas

The synthesis of new and innovative macrocyclic amidinoureas from linear di-Boc-guanidino-alkylamines related to guazatine was accomplished. The macrocyclization reaction proceeds under mild conditions affording 11- to 16-membered rings with a new and pre